Skip to main content
BIIB
NASDAQ Life Sciences

Biogen Reclassifies Apellis Acquisition as Non-Significant, Removes Pro Forma Financial Requirement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$194.24
Mkt Cap
$28.677B
52W Low
$121.05
52W High
$205.97
52W Position info
60% above low
Off High info
5.7% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BIIB sits 60% above its 52-week low of $121.05.

Summary

Biogen amended its acquisition filing, stating the Apellis Pharmaceuticals deal is not "significant" by SEC standards, thus removing the requirement for pro forma financial statements.


Key Events · M&A and Partnerships · BIIB

  • Acquisition Reclassification

    Biogen has reclassified its May 14, 2026 acquisition of Apellis Pharmaceuticals as "not significant" under Regulation S-X, a change from its initial assessment.

  • Removed Financial Reporting Requirement

    As a result of the reclassification, Biogen is no longer required to file separate financial statements for Apellis or pro forma financial information related to the merger.


Analysis · BIIB · Life Sciences

Biogen filed an amendment to its May 14, 2026 8-K, which originally disclosed the consummation of the Apellis Pharmaceuticals acquisition. The company has now determined that the acquisition is not "significant" under Regulation S-X, meaning it is no longer required to file separate financial statements for Apellis or pro forma financial information related to the merger. This reclassification reduces the regulatory reporting burden and indicates the acquisition's financial impact is less material than initially assessed by the company.

How filings like this one have moved

In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BIIB was trading at $194.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.7B. The 52-week trading range was $121.05 to $205.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Aug 31, 2026, 7:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $216.65
Real-time Price: $217.36 info
Change: +$0.710 (+0.33%) info
Market Cap: $32.116B info
BIIB
Jul 29, 2026, 10:51 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $214.75
Real-time Price: $217.36 info
Change: +$2.62 (+1%) info
Market Cap: $32.116B info
BIIB
Jul 29, 2026, 6:36 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $204.29
Real-time Price: $217.36 info
Change: +$13.07 (+6%) info
Market Cap: $32.116B info
BIIB
Jul 29, 2026, 6:10 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $201.00
Real-time Price: $217.36 info
Change: +$16.36 (+8%) info
Market Cap: $32.116B info
BIIB
Jul 29, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $201.00
Real-time Price: $217.36 info
Change: +$16.36 (+8%) info
Market Cap: $32.116B info